NCT00641082

A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Bukwang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.

Conditions

• HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Interventions

Type	Name	Description
DRUG	Clevudine	30mg for 48 weeks
DRUG	Adefovir dipivoxil	10mg for 48 weeks

Timeline

• Start date: 2008-02-01
• Primary completion: 2012-03-01
• First posted: 2008-03-21
• Last updated: 2012-04-25

Locations

2 sites across 1 country: South Korea